Efficient Targeting of Head and Neck Squamous Cell Carcinoma by Systemic Administration of a Dual uPA and MMP-Activated Engineered Anthrax Toxin by Schafer, Jeffrey M. et al.
Efficient Targeting of Head and Neck Squamous Cell
Carcinoma by Systemic Administration of a Dual uPA and
MMP-Activated Engineered Anthrax Toxin
Jeffrey M. Schafer
1., Diane E. Peters
1,2., Thomas Morley
3., Shihui Liu
3, Alfredo A. Molinolo
1, Stephen H.
Leppla
3, Thomas H. Bugge
1*
1Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, United States of America,
2Program of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts, United States of America, 3Bacterial Toxins and
Therapeutics Section, Laboratory of Bacterial Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States
of America
Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Although considerable
progress has been made in elucidating the etiology of the disease, the prognosis for individuals diagnosed with HNSCC
remains poor, underscoring the need for development of additional treatment modalities. HNSCC is characterized by the
upregulation of a large number of proteolytic enzymes, including urokinase plasminogen activator (uPA) and an assortment
of matrix metalloproteinases (MMPs) that may be expressed by tumor cells, by tumor-supporting stromal cells or by both.
Here we explored the use of an intercomplementing anthrax toxin that requires combined cell surface uPA and MMP
activities for cellular intoxication and specifically targets the ERK/MAPK pathway for the treatment of HNSCC. We found that
this toxin displayed strong systemic anti-tumor activity towards a variety of xenografted human HNSCC cell lines by
inducing apoptotic and necrotic tumor cell death, and by impairing tumor cell proliferation and angiogenesis. Interestingly,
the human HNSCC cell lines were insensitive to the intercomplementing toxin when cultured ex vivo, suggesting that either
the toxin targets the tumor-supporting stromal cell compartment or that the tumor cell requirement for ERK/MAPK
signaling differs in vivo and ex vivo. This intercomplementing toxin warrants further investigation as an anti-HNSCC agent.
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Introduction
With more than 500,000 new cases diagnosed each year, head
and neck squamous cell carcinoma (HNSCC) represents the sixth
most common cancer worldwide [1]. Although the risk factors and
the molecular pathways that underlie HNSCC development are
by now well-known, the five-year survival rate after diagnosis is
low and has remained unchanged for many decades [2–6].
The overexpression, prognostic significance, and causal in-
volvement of extracellular/pericellular proteases in the progres-
sion of HNSCC have been extensively studied (reviewed in
[7–10]). The multiple proteases that are expressed at very high
levels by either tumor cells, stromal cells or both include urokinase
plasminogen activator (uPA), tissue plasminogen activator, matrix
metalloproteinase (MMP)-1, -2, -3, -7, -9, -10, -11, -13, and -14,
cathepsins B, D, H, and L, kallikreins 5, 7, 8, and 10, and
matriptase [11–32].
Anthrax toxin is a three-component toxin secreted by Bacillus
anthracis that consists of protective antigen (PA, 83 kDa), lethal
factor (LF, 90 kDa), and edema factor (EF, 90 kDa) [33]. To
intoxicate cells, PA binds to either of two widely-expressed cell
surface receptors, tumor endothelial marker 8 (TEM8, also
‘‘ANTXR1’’) or capillary morphogenesis gene 2 product
(CMG2, also ‘‘ANTXR2’’) [34–37], and subsequently is cleaved
at the sequence
164RKKR
167 by cell-surface furin or furin-like
proteases, which are ubiquitously expressed by cells [38,39]. This
cleavage is essential for all subsequent steps of intoxication. The
newly generated C-terminal 63-kDa fragment of PA remains
bound to its cell surface receptor and forms a heptamer that binds
and translocates up to three molecules of LF or EF into the cytosol
to induce their cytotoxic effects. EF is a potent adenylate cyclase
that intoxicates cells by raising cAMP levels, whereas LF is a
metalloproteinase that cleaves and inactivates mitogen-activated
protein kinase kinases (MEKs), thereby blocking the extracellular
signal-regulated kinase (ERK)/mitogen activated protein kinase
(MAPK) pathway [40–45].
Strategies to therapeutically exploit the signature overexpression
of proteolytic enzymes in cancer have mostly focused on inhibiting
their enzymatic activity so as to blunt invasive and metastatic
processes [46–48]. More recently, however, strategies have been
devised to generate tumor cytotoxic pro-drugs that are activated
by specific tumor-expressed proteases [49–51]. In this regard, we
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toxin that requires the combined activities of both cell surface uPA
and MMP for cytotoxicity, and showed that this toxin has a greatly
diminished off-target cytotoxicity when compared to native
anthrax toxin [52]. The intercomplementing toxin consists of
PA-U2-R200A, which is a reengineered PA that is activated by
uPA and PA-L1-I210A, which is a reengineered PA that is
activated by MMPs. PA-U2-R200A and PA-L1-I210A also each
harbor additional, but different, mutations in the LF/EF binding
site that make heptamers composed of PA-U2-R200A alone or of
PA-L1-I210A alone unable to bind EF or LF and support their
translocation to the cytoplasm. However, heptamers that are
composed of a mixture of PA-U2-R200A and PA-L1-I210A can
form functional EF/LF binding sites in by intermolecular
complementation.
Because of the consistent expression of both uPA and several
MMPs by human HNSCC, here we explored the potential use of
this toxin as a novel targeted treatment for this disease. Indeed, we
found that systemic administration of the intercomplementing
toxin caused regression of several xenografted human HNSCC.
Interestingly, the in vivo efficacy of the toxin was independent of the
sensitivity of the cultured tumor cells to the toxin, suggesting that
the intercomplementing toxin may inhibit tumor growth by




All animal work was performed in accordance with protocols
approved by the National Institute of Dental and Craniofacial
Research Animal Care and Use Committee (Animal Study
Proposal Numbers: 09-523 and 10-585).
Protein purification
Recombinant PA, PA-U2-R200A, PA-L1-I210A, LF, and FP59
were generated and purified as previously described [52-54]. The
LF used here is a recombinant protein having a non-native N-
terminal sequence of HMAGG [55].
Cell culture
The human HNSCC cell lines Cal27, Hep2, HN6, HN12,
HN30 [56–58], the cervical carcinoma cell line HeLa [59], and
the human colon carcinoma cell line HT29 [60] have been
described. All cell lines were cultured in a humidified 5% CO2
environment at 37uC. Cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin (Invitrogen, Carls-
bad, CA).
In vitro cytotoxicity assays
The cytotoxicity of PA-U2-R200A and PA-L1-I210A, with LF
or FP59, was assessed using a colorimetric 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in 96-well
plates [61]. Cells exhibiting ,40% confluence were incubated
with serial dilutions of PA (0–10 nM) or PA-U2-R200A + PA-L1-
I210A (0–10 nM) and either FP59 (1.9 nM) or LF (5.5 nM) to a
final volume of 200 ml per well. Cell viability was determined after
48 h.
Animals
Female Hsd:Athymic Nude-Foxn1nu mice (Harlan Laborato-
ries Inc., Indianapolis, IN) between 4 and 6 weeks of age were used
in this study. Animals were housed in a pathogen-free environ-
ment certified by the Association for Assessment and Accreditation
of Laboratory Animal Care International.
In vivo tumor xenograft model
Cells (9610
5 per mouse) were injected intradermally in the mid-
scapular dorsal region of each mouse as described [62]. When
tumors reached a volume of 50–100 mm
3, the mice were divided
into two groups of ten mice with equivalent median tumor sizes.
Treatment was initiated on day 0. Mice received intraperitoneal
(I.P.) injections of either 100 or 500 ml PBS or PA-U2-R200A +
PA-L1-I210A + LF in 100 or 500 ml PBS, respectively. Mice
bearing HN12 xenografts were administered 25 mg PA-U2-R200A
+25 mg PA-L1-I210A +17 mg LF, while mice bearing Cal27, HN6
and Hep2 xenografts were treated with 20 mg PA-U2-R200A
+20 mg PA-L1-I210A +13 mg LF. Mice received five injections
total using a Monday, Wednesday, Friday dosing schedule. An
investigator unaware of the treatment group measured the longest
and shortest tumor diameters with digital calipers (FV Fowler
Company, Inc., Newton, MA). Tumor volume was estimated
using the equation V = (length in mm * (width in mm)
2)/2 [63].
The statistical significance of differences in tumor sizes and mouse
weight was determined by the two-tailed Student’s t-test using
Microsoft Excel software. During the 11-day treatment period, no
animals in either the control or treatment groups met the criteria
for early euthanasia: frank tumor ulceration or tumor mass
exceeding 10% of body weight.
Histopathological analysis
HN12 (n=5) and Hep2 (n=4) tumor-bearing nude mice were
treated I.P. with 100 or 500 ml PBS or with 15 mg PA-U2-R200A
+15 mg PA-L1-I210A +10 mg LF in 100 or 500 ml PBS on days 0,
2 and 4. The mice were euthanized by CO2 inhalation 24 h after
the last injection. Tumors were excised, fixed in 4% paraformal-
dehyde for 24 h, embedded in paraffin, sectioned, and stained
with hematoxylin and eosin (H&E). Sections with identifiable
carcinoma cells in the H&E sections were also stained with a
monoclonal rabbit anti-mouse PECAM-1 (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA) and a polyclonal rabbit anti-human
Ki67 (Novocastra Laboratories, Ltd., Newcastle, UK). TUNEL
staining was performed by Histoserv, Inc. (Germantown, MD).
Images were captured using an Aperio T3 Scanscope (Aperio
Technologies, Vista, CA) and were quantified using Aperio
Imagescope Software (Aperio Technologies, Vista, CA) by a
blinded investigator. Statistical significance of differences for
apoptosis, cellular proliferation and tumor vascularization were
determined using the Student’s t-test, two-tailed, using GraphPad
Prism software. Statistical significance of differences for necrosis
was determined using the Mann-Whitney U-test using GraphPad
Prism software.
Results
We first explored if HNSCC cells express functional anthrax
toxin receptors by exposing the five human HNSCC cell lines,
Cal27, Hep2, HN6, HN12, and HN30 to increasing concentra-
tions of PA in combination with 1.9 nM FP59 (Figure 1A). FP59 is
a fusion protein consisting of LF residues 1–254 with the ADP-
ribosylation domain of Pseudomonas exotoxin A. When translocated
to the cytoplasm via PA, FP59 efficiently kills all cells by ADP-
ribosylation and inhibition of translation elongation factor 2 [64].
PA in combination with FP59 killed all HNSCC cell lines with an
LD50 ranging from less than 7 to 400 pM demonstrating the
presence of functional anthrax toxin receptors. To assess if these
HNSCC cell lines also express both functional uPA and MMP cell
Oral Cancer Treatment with Modified Anthrax Toxin
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lines to the same concentration of FP59 in combination with
increasing concentrations of intercomplementing PA (PA-U2-
R200A + PA-L1-I210A) (Figure 1B). Three of the HNSCC cell
lines (Cal27, HN6, HN12) were sensitive to the intercomplement-
ing toxin (LD50, 0.5 nM to 8 nM), demonstrating functional uPA
and MMP expression, while the two other cell lines, Hep2 and
HN30 were resistant, indicating the absence of either functional
uPA or MMP activity, or both. We next determined if the five
HNSCC cell lines were dependent on a functional MEK/MAPK
pathway for growth in culture by incubating them with 5.5 nM LF
in combination with increasing concentrations of either wildtype
PA (Figure 1C) or intercomplementing PA (Figure 1D). None of
the HNSCC cell lines were sensitive to the two toxin combina-
tions, showing that MEK activity is dispensable for HNSCC cell
growth in culture.
Cal27, Hep2, HN6, and HN12 HNSCC cell lines form solid
tumors when xenografted to immunocompromized mice and were
therefore suitable for assessing the efficacy of the intercomple-
menting toxin for HNSCC treatment in vivo. The four cell lines
were transplanted intradermally to nude mice, and solid tumor
nodules constituting 0.25 to 0.5 percent of the total body weight
Figure 1. Cytotoxicity of intercomplementing anthrax lethal toxins to human HNSCC cell lines. Cal27 (blue triangles), Hep2 (purple
triangles), HN6 (green squares), HN12 (purple squares), and HN30 (yellow diamonds) cells were incubated with increasing concentrations of wildtype
PA in combination with FP59 (A), intercomplementing PA (PA-U2-R200A + PA-L1-I210A) in the presence of FP59 (B), wildtype PA with LF (C)o r
intercomplementing PA with LF (D) for 48 h. The cell viability was then measured using an MTT assay. HT29 colon carcinoma (grey circles) and HeLa
(red circles) cells were used as a positive and negative controls, respectively [52,74]. Cell survival is expressed as mean viability 6 standard deviation
of the mean.
doi:10.1371/journal.pone.0020532.g001
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times per week with intraperitoneal injections of either inter-
complementing toxin in combination with LF or with PBS as a
control (Figure 2). Cal27, HN6, and HN12 tumors were all
efficiently treated with the intercomplementing toxin, consistent
with their expression of functional cell surface uPA and MMP
activities in cell culture (Figure 2A-C). Average tumor sizes in
toxin-treated mice ranged from 0.6 to 26 percent of the average
tumor sizes of PBS-injected mice at treatment cessation.
Interestingly, although Hep2 cells did not express uPA or MMP
activity sufficient for intercomplementing toxin activation in
culture (see above), the Hep2 tumors were treated efficiently in
vivo, with the average tumor size of toxin-treated mice being just
six percent of the average tumor sizes of PBS-injected mice at
treatment cessation (Figure 2D). The greatest response to the
intercomplementing toxin was observed with HN12-bearing mice,
with 40 percent of the mice remaining tumor-free when observed
for up to one year after treatment cessation.
The toxin was generally well tolerated. Two of 40 (five percent)
of the toxin-treated mice died within the treatment period,
whereas no death was observed in PBS-treated groups (P=N. S.,
Chi-square test, two tailed). The largest weight loss in toxin-treated
mice as compared to PBS-treated mice (Figure 2E) was observed at
day 11 in all trials. Excluding the mass attributed to tumor burden,
Figure 2. Tumoricidal activity of intermolecular complementing PA to human HNSCC. Nude mice bearing intradermal Cal27 (A), HN6 (B),
HN12 (C), and Hep2 (D) HNSCC xenografts were injected intraperitoneally with either PBS (blue lines) or PA-U2-R200A + PA-L1-I210A + LF (red lines)
at the time points indicated by the red arrows. (E) Body weight change over time in all groups. The data are expressed as mean tumor weight 6
standard error of the mean; *, P,0.01. Ten mice were used per tumor and treatment group.
doi:10.1371/journal.pone.0020532.g002
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lower than the average body weight for all mice in PBS-treatment
groups (P,0.0004, Student’s t-test, two-tailed).
We next examined the mechanistic basis for the potent systemic
anti-HNSCC activity of the intercomplementing toxin. For this
purpose HN12 (sensitive to intercomplementing toxin administered
with FP59 in vitro) and Hep2 cells (insensitive to intercomplementing
toxinadministeredwith FP59invitro)weretransplanted tomice,and
established tumors were treated three times with toxin or PBS. The
tumors were then excised (at day 5, as per Figure 2), and histological
sections were generated, scanned, and subjected to an unbiased
quantitative histomorphometric analysis. No tumor tissue was
identified in histological sections from two of five examined HN12
toxin-treated tumors, indicating complete tumor regression. The
three remaining toxin-treated HN12 tumors presented with a four-
foldincreaseintheareaoftumornecrosis,ascomparedtountreated
Figure 3. Increased necrosis and apoptosis and decreased proliferation and vessel density of human HN12 xenografts in
intercomplementing toxin-treated mice. Necrosis (A), proliferation (B), tumor vascularization (C), and apoptosis (D) of HN12 xenografts 5 days
after initiation of systemic treatment with either PBS (blue bars and left panels) or intercomplementing toxin (red bars and right panels). A,
hematoxylin and eosin staining. B, Ki67 staining. C, PECAM-1 staining. D, TUNEL staining. The arrows in D highlight examples of TUNEL positive cells.
Columns, mean; bars, standard error of the mean, *, P,0.05. In all cases, representative images are shown. Scale Bars; 100 mM.
doi:10.1371/journal.pone.0020532.g003
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of these toxin-treated tumors was more than twelve-fold reduced, as
determined by staining of the cell proliferation marker, Ki67
(Figure 3B). Vessel density was likewise reduced by three-fold
(Figure 3C), while the apoptotic index was increased 13-fold
(Figure 3D). Interestingly, unlike the case for the HN12 tumors
examined above, the intercomplementing toxin primarily targeted
Hep2 tumors by inducing necrosis (Figure 4). Thus, necrosis was
increased by more than 13-fold (Figure 4A), while cell proliferation,
vessel densities, and apoptotic indices in the remaining viable areas
of the xenografted Hep2 tumors were all unaffected by treatment
with intercomplementing toxin (Figure 4B-D). The retention of
these latter tumor properties was notable given the striking decrease
in tumor mass (Figure 2D, day 5).
Figure 4. Intercomplementing toxin induces massive tumor necrosis in xenografted human Hep2 tumors, but does not affect
proliferation, vascularization or apoptosis in viable tumor areas. Necrosis (A), proliferation (B), tumor vascularization (C), and apoptosis (D)
of Hep2 xenografts five days after initiation of systemic treatment with either PBS (blue bars and left panels) or intercomplementing toxin (red bars
and right panels). A, hematoxylin and eosin staining. B, Ki67 staining. C, PECAM-1 staining. D, TUNEL staining. N in A and B indicates necrotic area.
Tumor margins in A–C are indicated with dotted lines. Arrows in D highlight examples of TUNEL positive cells. Columns, mean; bars, standard error of
the mean, *, P,0.05. In all cases, representative images are shown. Scale Bars; 100 mM.
doi:10.1371/journal.pone.0020532.g004
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Research over the last decade has led to the generation of
several modified anthrax toxin-based candidate anti-tumor
compounds that exploit the signature overexpression of extracel-
lular proteases by tumor cells and the cellular components of the
tumor stroma to achieve tumor selectivity [52,53,65–74]. In the
current study we performed a comprehensive analysis of the
suitability of one of these compounds: an intercomplementing
toxin for the treatment of HNSCC. A unique property of this toxin
is its inclusion of no less than three specificity determinants: the
requirement for both cell surface uPA activity and cell surface
MMP activity, combined with selective toxicity to cells dependent
on the MEK/MAPK kinase pathway for survival [42,52].
Xenograft studies revealed that the intercomplementing toxin
displayed excellent systemic antitumor activity towards all of the
four analyzed HNSCC cell lines. By using a treatment regimen
consisting of five intraperitoneal toxin injections, we achieved
effects ranging from tumor stasis to complete tumor eradication, as
defined by the absence of relapse in mice that were followed for up
to one year after treatment cessation.
A notable observation in the current study was that sensitivity to
LF or expression of functional cell surface uPA and MMP activity
by cultured HNSCC cell lines were poor predictors of the in vivo
sensitivity of the tumor to the intercomplementing toxin. Thus,
although all of the four tumors resulting from the HNSCC cell
lines were efficiently treated with the intercomplementing toxin
when xenografted to mice, none of the cell lines displayed
significant sensitivity to LF in culture (wildtype PA with LF,
Figure 1C), and one cell line did not express sufficient cell surface
uPA and MMP activity for functional PA heptamer formation
(Hep2 cells, intercomplementing toxin with FP59, Figure 1B). Two
possible, and not mutually exclusive, explanations for this
observation can be offered. First, the repertoire of cell surface
proteases expressed by the tumor cells or their requirement for the
ERK/MAPK pathway for proliferation and survival may differ in
culture and in vivo. Secondly, the intercomplementing toxin may
exert its anti-tumor activity by targeting the cellular component of
the HNSCC tumor stroma (tumor-associated inflammatory cells,
fibroblasts, endothelial cells) [75]. In direct support of the latter,
we have previously shown that LF can efficiently impair the
growth of a xenografted immortalized ovarian cell line that was
made genetically deficient in anthrax toxin receptors [69]. It also
remains a possibility that activation of the intercomplementing
toxin by proteases different from uPA and MMPs account for the
in vivo efficacy of the intercomplementing toxin. This, however, is
unlikely to be the case. First, cleavage of MMP-activated PA and
subsequent cellular intoxication can be blocked completely by the
synthetic MMP inhibitors BB94 (Batimastat), BB2516 (Marima-
stat), and GM6001, as well as tissue inhibitor of matrix
metalloproteinases-2. Cleavage of the uPA-activated PA and
cellular intoxication on the other hand can be prevented by
plasminogen activator inhibitor-1 and by antibodies and also by
protein fragments that block the binding of uPA to its cellular
receptor. Finally, using mice genetically deficient in components of
the plasminogen activation system, we have previously shown that
the anti-tumor activity of the uPA-activated PA in vivo is dependent
on cell surface uPA activity [52,53,73,74,76].
Histological analysis of HN12 and Hep2 xenografts revealed
markedly different effects of systemic intercomplementing toxin
treatment on the two tumors. While toxin-treated HN12 xenografts
displayed decreased proliferation and an increase in both apoptotic
and necrotic cell death, neither proliferation or apoptosis was
affected by toxin treatment of Hep2 xenografts. Rather, the potent
anti-tumor activity of the intercomplementing toxin was caused
exclusively by the induction of tumor necrosis. In light of the
inability of cultured Hep2 cells to express sufficient uPA and MMP
activity for cellular intoxication, it is tempting to speculate that
tumor necrosis in Hep2 xenografts is induced by a vascular collapse
causedbydirecttargeting ofthe tumorvasculatureorotheressential
cellular components of the tumor stroma.
The anti-tumor efficacy of the intercomplementing toxin and
tolerability at administered doses highlight the therapeutic
potential of this agent. Procedures for recombinant expression
and purification of large quantities of anthrax toxins in avirulent
strains of Bacillus anthracis and Eschericia coli are already established
and will not represent an impediment to the therapeutic
development of the intercomplementing toxin for treatment of
HNSCC. The pharmacology and pharmacokinetics of wildtype
PA and LF are well studied, and the intercomplementing PA could
be expected to display pharmacological and pharmacokinetic
properties similar to or even more favorable that those of wildtype
PA due to enhanced plasma stability [69,77–79]. Systematic
animal toxicity studies required for the clinical introduction of the
intercomplementing toxin are in progress (D. E. P., S. H. L., and
T. H. B., unpublished data).
The absence of correlation between in vivo efficacy and sensitivity of
culturedHNSCCcelllinestotheintercomplementingtoxindiscussed
above raise interesting questions as to the potential for prescreening
HNSCC patients for treatment. Based on our findings, assaying
toxin-sensitivity of cultured primary tumor cell explants may be of
limited value. However, determination of tumor cell and stromal cell
uPA and MMP protein expression or enzymatic activity in resected
tumors or needle biopsies may be a clinically useful predictor of
treatment efficacy.
In summary, we have shown that an intercomplementing toxin
specifically targeting ERK/MAPK-dependent cells with high cell
surface uPA and MMP activity holds promise as a novel candidate
drug for the treatment of HNSCC. Future research towards the
clinical development of this toxin is warranted.
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